Suppr超能文献

鉴定和验证跨物种和肿瘤类型的肿瘤浸润性 Treg 转录特征。

Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types.

机构信息

Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115.

Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114.

出版信息

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10672-E10681. doi: 10.1073/pnas.1810580115. Epub 2018 Oct 22.

Abstract

FoxP3 T regulatory (Treg) cells are central elements of immunologic tolerance. They are abundant in many tumors, where they restrict potentially favorable antitumor responses. We used a three-pronged strategy to identify genes related to the presence and function of Tregs in the tumor microenvironment. Gene expression profiles were generated from tumor-infiltrating Tregs (TITRs) of both human and mouse tumors and were compared with those of Tregs of lymphoid organs or normal tissues from the same individuals. A computational deconvolution of whole-tumor datasets from the Cancer Genome Atlas (TCGA) was performed to identify transcripts specifically associated with Tregs across thousands of tumors from different stages and locations. We identified a set of TITR-differential transcripts with striking reproducibility between tumor types in mice, between mice and humans, and between different human patients spanning tumor stages. Many of the TITR-preferential transcripts were shared with "tissue Tregs" residing in nonlymphoid tissues, but a tumor-preferential segment could be identified. Many of these TITR signature transcripts were confirmed by mining of TCGA datasets, which also brought forth transcript modules likely representing the parenchymal attraction of, or response to, tumor Tregs. Importantly, the TITR signature included several genes encoding effective targets of tumor immunotherapy. A number of other targets were validated by CRISPR-based gene inactivation in mouse Tregs. These results confirm the validity of the signature, generating a wealth of leads for understanding the role of Tregs in tumor progression and identifying potential targets for cancer immunotherapy.

摘要

FoxP3+ 调节性 T(Treg)细胞是免疫耐受的核心要素。它们在许多肿瘤中丰富存在,限制了潜在有利的抗肿瘤反应。我们采用三管齐下的策略来鉴定与肿瘤微环境中 Treg 的存在和功能相关的基因。从人类和小鼠肿瘤浸润性 Treg(TITR)中生成基因表达谱,并与来自同一个体的淋巴器官或正常组织中的 Treg 进行比较。对癌症基因组图谱(TCGA)中的全肿瘤数据集进行计算反卷积,以鉴定在来自不同阶段和位置的数千个肿瘤中与 Treg 特异性相关的转录本。我们鉴定了一组 TITR 差异转录本,这些转录本在小鼠、小鼠和人类以及不同人类患者之间的肿瘤类型中具有惊人的重现性,跨越了肿瘤阶段。许多 TITR 偏好转录本与存在于非淋巴组织中的“组织 Treg”共享,但可以鉴定出肿瘤偏好片段。通过对 TCGA 数据集的挖掘,对许多这些 TITR 特征转录本进行了验证,这也提出了可能代表肿瘤 Treg 实质吸引力或对其反应的转录本模块。重要的是,TITR 特征包括几个编码肿瘤免疫治疗有效靶点的基因。通过在小鼠 Treg 中基于 CRISPR 的基因失活验证了其他一些靶点。这些结果证实了该特征的有效性,为理解 Treg 在肿瘤进展中的作用并确定癌症免疫治疗的潜在靶点提供了丰富的线索。

相似文献

6
Roles of regulatory T cells in cancer immunity.调节性T细胞在癌症免疫中的作用。
Int Immunol. 2016 Aug;28(8):401-9. doi: 10.1093/intimm/dxw025. Epub 2016 May 9.

引用本文的文献

3
Immunometabolism of regulatory T cells in cancer.癌症中调节性T细胞的免疫代谢
Oncogene. 2025 Jul;44(25):2011-2024. doi: 10.1038/s41388-025-03458-1. Epub 2025 Jun 4.

本文引用的文献

6
Interferon-γ Drives T Fragility to Promote Anti-tumor Immunity.γ干扰素促使T细胞脆弱性以促进抗肿瘤免疫。
Cell. 2017 Jun 1;169(6):1130-1141.e11. doi: 10.1016/j.cell.2017.05.005. Epub 2017 May 25.
9
Toward a Shared Vision for Cancer Genomic Data.迈向癌症基因组数据的共同愿景。
N Engl J Med. 2016 Sep 22;375(12):1109-12. doi: 10.1056/NEJMp1607591.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验